This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Alert me on articles by topic

Hagen Blaszyk, MD; Johannes Björnsson, MD

Arch Surg. 2000;135:1410-1413.

Hypothesis  Currently, the risk for postoperative acute pulmonary embolism (APE) is assessed clinically. We hypothesize that the expensive screening for the most common genetic thrombophilic clotting defect (factor V Leiden; R⁵⁰⁶Q) after exclusion of established clinical risk factors does not offer additional benefit to surgical patients.

Design  We reviewed protocols and histories from 8249 consecutive autopsies performed at the Mayo Clinic, Rochester, Minn. All patients who died of APE after routine surgery and who lacked any other clinical risk factors for APE were included and compared with matched controls. Genomic DNA was extracted from archival tissues and examined for R⁵⁰⁶Q by polymerase chain reaction amplification, restriction enzyme digestion, and direct sequencing.

Results  Acute pulmonary embolism was the immediate cause of death in 454 patients (5.5%). Of those, 32 (7.0%) had undergone routine surgery. These patients represent less than 0.07% of all case-adjusted surgical procedures in the same period. The rate of postoperative death from APE was higher after neurosurgical procedures (0.3%) than all other procedures (0.04%). Sixteen patients (50.0%) were morbidly obese. Only 1 patient was heterozygous and none were homozygous for R⁵⁰⁶Q.

Conclusions  (1) Fatal APE is uncommon in surgical patients lacking clinically apparent risk factors for venous thromboembolism. (2) Neurosurgical patients are at increased risk for postoperative APE. (3) Morbid obesity is a major independent risk factor in cases of sudden death from APE postoperatively. (4) Routine preoperative screening for R⁵⁰⁶Q in the factor V gene does not appear to offer additional benefit in surgical patients without clinically recognizable thromboembolic risk factor(s).

From the Division of Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minn.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Predictors of mortality following symptomatic pulmonary embolism in patients undergoing noncardiac surgery: [Les indicateurs de mortalite a la suite d'embolies pulmonaires symptomatiques chez des patients subissant une chirurgie non cardiaque]
Comfere et al.
Canadian J. Anesthesia 2007;54:634-641.
ABSTRACT | FULL TEXT  

Perioperative management of the obese orthopaedic patient.
Guss and Bhattacharyya
J Am Acad Orthop Surg 2006;14:425-432.
ABSTRACT | FULL TEXT  

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
Poirier et al.
Circulation 2006;113:898-918.
ABSTRACT | FULL TEXT  

Factor V Leiden and Perioperative Risk
Donahue
Anesth. Analg. 2004;98:1623-1634.
ABSTRACT | FULL TEXT  

British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
Thorax 2003;58:470-483.
FULL TEXT  

Anesthetic Considerations for Bariatric Surgery
Ogunnaike et al.
Anesth. Analg. 2002;95:1793-1805.
FULL TEXT  

Treatment Considerations for Inherited Thrombophilia and Pulmonary Embolus
Baker
Arch Surg 2001;136:237-237.
FULL TEXT